{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T13:45:03Z","timestamp":1772631903678,"version":"3.50.1"},"reference-count":123,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.clml.2024.09.001","type":"journal-article","created":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T17:46:37Z","timestamp":1726163197000},"page":"226-239","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["SOHO State of the Art Updates and Next Questions | Choosing and Properly Using a JAK Inhibitor in Myelofibrosis"],"prefix":"10.1016","volume":"25","author":[{"given":"Michael J.","family":"Hochman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colin A.","family":"Vale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9819-4151","authenticated-orcid":false,"given":"Anthony M.","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.clml.2024.09.001_bib0001","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2024.09.001_bib0002","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2024.09.001_bib0003","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"7037","key":"10.1016\/j.clml.2024.09.001_bib0004","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"issue":"17","key":"10.1016\/j.clml.2024.09.001_bib0005","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"issue":"9464","key":"10.1016\/j.clml.2024.09.001_bib0006","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.clml.2024.09.001_bib0007","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.clml.2024.09.001_bib0008","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med"},{"issue":"10","key":"10.1016\/j.clml.2024.09.001_bib0009","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients","volume":"108","author":"Pardanani","year":"2006","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.clml.2024.09.001_bib0010","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.clml.2024.09.001_bib0011","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.clml.2024.09.001_bib0012","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1182\/blood-2014-02-554634","article-title":"Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis","volume":"123","author":"Rampal","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.09.001_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100691","article-title":"A provider's guide to primary myelofibrosis: pathophysiology, diagnosis, and management","volume":"45","author":"Garmezy","year":"2021","journal-title":"Blood Rev"},{"issue":"9","key":"10.1016\/j.clml.2024.09.001_bib0014","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clml.2024.09.001_bib0015","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13045-017-0417-z","article-title":"Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial","volume":"10","author":"Verstovsek","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"9","key":"10.1016\/j.clml.2024.09.001_bib0016","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.clml.2024.09.001_bib0017","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/leu.2016.148","article-title":"Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis","volume":"30","author":"Harrison","year":"2016","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.clml.2024.09.001_bib0018","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13045-017-0527-7","article-title":"Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses","volume":"10","author":"Verstovsek","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"2","key":"10.1016\/j.clml.2024.09.001_bib0019","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1182\/bloodadvances.2021006006","article-title":"Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study","volume":"6","author":"Guglielmelli","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.clml.2024.09.001_bib0020","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/bjh.13379","article-title":"Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial","volume":"170","author":"Mead","year":"2015","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.clml.2024.09.001_bib0021","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.3324\/haematol.2016.143677","article-title":"Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial","volume":"101","author":"Al-Ali","year":"2016","journal-title":"Haematol"},{"issue":"1","key":"10.1016\/j.clml.2024.09.001_bib0022","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/hon.2429","article-title":"Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: results from an independent study","volume":"36","author":"Palandri","year":"2018","journal-title":"Hematol Oncol"},{"issue":"5","key":"10.1016\/j.clml.2024.09.001_bib0023","doi-asserted-by":"crossref","first-page":"947","DOI":"10.3324\/haematol.2018.204602","article-title":"EXPAND, a dose-finding study of ruxolitinib in patients with myelofibrosis and low platelet counts: 48-week follow-up analysis","volume":"104","author":"Vannucchi","year":"2019","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.clml.2024.09.001_bib0024","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1038\/s41375-021-01261-x","article-title":"Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study","volume":"35","author":"Cervantes","year":"2021","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.clml.2024.09.001_bib0025","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/s41375-018-0028-x","article-title":"Sex and degree of severity influence the prognostic impact of anemia in primary myelofibrosis: analysis based on 1109 consecutive patients","volume":"32","author":"Nicolosi","year":"2018","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.clml.2024.09.001_bib0026","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.3109\/10428194.2016.1146950","article-title":"Impact of ruxolitinib treatment on the hemoglobin dynamics and the negative prognosis of anemia in patients with myelofibrosis","volume":"57","author":"Al-Ali","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"10.1016\/j.clml.2024.09.001_bib0027","doi-asserted-by":"crossref","first-page":"e482","DOI":"10.3324\/haematol.2016.151449","article-title":"The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies","volume":"101","author":"Gupta","year":"2016","journal-title":"Haematol"},{"issue":"45","key":"10.1016\/j.clml.2024.09.001_bib0028","doi-asserted-by":"crossref","first-page":"79073","DOI":"10.18632\/oncotarget.18674","article-title":"Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis","volume":"8","author":"Palandri","year":"2017","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.clml.2024.09.001_bib0029","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1080\/10428194.2020.1845334","article-title":"Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study","volume":"62","author":"Gupta","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.clml.2024.09.001_bib0030","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/ajh.24976","article-title":"Ruxolitinib-associated infections: a systematic review and meta-analysis","volume":"93","author":"Lussana","year":"2018","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.clml.2024.09.001_bib0031","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/hon.2509","article-title":"Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients","volume":"36","author":"Polverelli","year":"2018","journal-title":"Hematol Oncol"},{"issue":"2","key":"10.1016\/j.clml.2024.09.001_bib0032","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jaad.2021.10.004","article-title":"A 10-year retrospective cohort study of ruxolitinib and association with nonmelanoma skin cancer in patients with polycythemia vera and myelofibrosis","volume":"86","author":"Lin","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.clml.2024.09.001_bib0033","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1182\/bloodadvances.2019000954","article-title":"Fedratinib in myelofibrosis","volume":"4","author":"Mullally","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.clml.2024.09.001_bib0034","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41375-020-0954-2","article-title":"Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis","volume":"35","author":"Talpaz","year":"2021","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.clml.2024.09.001_bib0035","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","article-title":"Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial","volume":"1","author":"Pardanani","year":"2015","journal-title":"JAMA Oncol"},{"issue":"7","key":"10.1016\/j.clml.2024.09.001_bib0036","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1016\/S2352-3026(17)30088-1","article-title":"Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study","volume":"4","author":"Harrison","year":"2017","journal-title":"Lancet Haematol"},{"issue":"6","key":"10.1016\/j.clml.2024.09.001_bib0037","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/ajh.25777","article-title":"Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure","volume":"95","author":"Harrison","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2024.09.001_bib0038","doi-asserted-by":"crossref","unstructured":"Harrison CN, Mesa R, Talpaz M, et al. Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib: results from the phase 3 randomized FREEDOM2 study. Blood. 2023;142(Supplement 1):3204. doi:10.1182\/blood-2023-173391. Retrieved from https:\/\/www.ash.confex.com\/ash\/2023\/webprogram\/Paper173391.html. Accessed September 26th, 2024.","DOI":"10.1182\/blood-2023-173391"},{"issue":"4","key":"10.1016\/j.clml.2024.09.001_bib0039","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1111\/bjh.18284","article-title":"Limited activity of fedratinib in myelofibrosis patients relapsed\/refractory to ruxolitinib 20\u2009mg twice daily or higher: a real-world experience","volume":"198","author":"Gangat","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2024.09.001_bib0040","doi-asserted-by":"crossref","unstructured":"Gupta V, Yacoub A, Mesa RA, et al. Safety and efficacy of fedratinib in patients with myelofibrosis previously treated with ruxolitinib: primary analysis of FREEDOM trial. Leukemia Lymphoma. 0(0):1-11. doi:10.1080\/10428194.2024.2346733.","DOI":"10.1080\/10428194.2024.2346733"},{"issue":"2","key":"10.1016\/j.clml.2024.09.001_bib0041","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.clml.2023.09.008","article-title":"Real-world use of fedratinib for myelofibrosis following prior ruxolitinib failure: patient characteristics, treatment patterns, and clinical outcomes","volume":"24","author":"Mascarenhas","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.09.001_bib0042","first-page":"4197","article-title":"Case series of potential wernicke's encephalopathy in patients treated with fedratinib","volume":"130","author":"Harrison","year":"2017","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2024.09.001_bib0043","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1002\/cncr.34722","article-title":"Ruxolitinib in cytopenic myelofibrosis: response, toxicity, drug discontinuation, and outcome","volume":"129","author":"Palandri","year":"2023","journal-title":"Cancer"},{"issue":"13","key":"10.1016\/j.clml.2024.09.001_bib0044","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.3390\/cancers15133331","article-title":"Association of myelofibrosis phenotypes with clinical manifestations, molecular profiles, and treatments","volume":"15","author":"Chifotides","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.clml.2024.09.001_bib0045","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jamaoncol.2017.5818","article-title":"Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial","volume":"4","author":"Mascarenhas","year":"2018","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.clml.2024.09.001_bib0046","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1002\/jha2.591","article-title":"Risk-adjusted safety analysis of the oral JAK2\/IRAK1 inhibitor pacritinib in patients with myelofibrosis","volume":"3","author":"Pemmaraju","year":"2022","journal-title":"eJHaem"},{"issue":"1","key":"10.1016\/j.clml.2024.09.001_bib0047","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/MOH.0000000000000693","article-title":"IRAK1 and IRAK4 as emerging therapeutic targets in hematologic malignancies","volume":"29","author":"Bennett","year":"2022","journal-title":"Curr Opin Hematol"},{"issue":"19","key":"10.1016\/j.clml.2024.09.001_bib0048","doi-asserted-by":"crossref","first-page":"5835","DOI":"10.1182\/bloodadvances.2023010151","article-title":"Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis","volume":"7","author":"Oh","year":"2023","journal-title":"Blood Adv"},{"issue":"17","key":"10.1016\/j.clml.2024.09.001_bib0049","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1182\/blood-2013-02-484832","article-title":"Results of a phase 2 study of pacritinib (SB1518), a JAK2\/JAK2(V617F) inhibitor, in patients with myelofibrosis","volume":"125","author":"Komrokji","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2024.09.001_bib0050","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13045-016-0367-x","article-title":"Phase 1\/2 study of pacritinib, a next generation JAK2\/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies","volume":"9","author":"Verstovsek","year":"2016","journal-title":"J Hematol Oncol"},{"issue":"5","key":"10.1016\/j.clml.2024.09.001_bib0051","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1016\/S2352-3026(17)30027-3","article-title":"Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial","volume":"4","author":"Mesa","year":"2017","journal-title":"Lancet Haematol"},{"issue":"22","key":"10.1016\/j.clml.2024.09.001_bib0052","doi-asserted-by":"crossref","first-page":"5825","DOI":"10.1182\/bloodadvances.2020003314","article-title":"Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis","volume":"4","author":"Gerds","year":"2020","journal-title":"Blood Adv"},{"issue":"34","key":"10.1016\/j.clml.2024.09.001_bib0053","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1200\/JCO.2017.73.4418","article-title":"SIMPLIFY-1: A phase III randomized trial of momelotinib versus ruxolitinib in janus kinase inhibitor-na\u00efve patients with myelofibrosis","volume":"35","author":"Mesa","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clml.2024.09.001_bib0054","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/S2352-3026(17)30237-5","article-title":"Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial","volume":"5","author":"Harrison","year":"2018","journal-title":"Lancet Haematol"},{"issue":"10373","key":"10.1016\/j.clml.2024.09.001_bib0055","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0140-6736(22)02036-0","article-title":"Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study","volume":"401","author":"Verstovsek","year":"2023","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.clml.2024.09.001_bib0056","doi-asserted-by":"crossref","first-page":"e735","DOI":"10.1016\/S2352-3026(23)00174-6","article-title":"Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study","volume":"10","author":"Gerds","year":"2023","journal-title":"Lancet Haematol"},{"issue":"13","key":"10.1016\/j.clml.2024.09.001_bib0057","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1182\/blood-2016-09-740092","article-title":"Momelotinib inhibits ACVR1\/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents","volume":"129","author":"Asshoff","year":"2017","journal-title":"Blood"},{"issue":"33","key":"10.1016\/j.clml.2024.09.001_bib0058","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1200\/JCO.2012.42.3863","article-title":"Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs","volume":"30","author":"Emanuel","year":"2012","journal-title":"JCO"},{"issue":"11","key":"10.1016\/j.clml.2024.09.001_bib0059","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1200\/JCO.21.02246","article-title":"Disease modification in myelofibrosis: an elusive goal?","volume":"40","author":"Vachhani","year":"2022","journal-title":"JCO"},{"issue":"13","key":"10.1016\/j.clml.2024.09.001_bib0060","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1182\/blood-2015-03-635235","article-title":"The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis","volume":"126","author":"Deininger","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2024.09.001_bib0061","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.clml.2014.12.008","article-title":"Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I","volume":"15","author":"Mesa","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"10.1016\/j.clml.2024.09.001_bib0062","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.clml.2024.02.015","article-title":"SOHO state of the art updates and next questions | early intervention in myelofibrosis: where are we and does it matter?","volume":"24","author":"Yacoub","year":"2024","journal-title":"Clin Lymphoma, Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.clml.2024.09.001_bib0063","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/HS9.0000000000000001","article-title":"Myelofibrosis-related anemia: current and emerging therapeutic strategies","volume":"1","author":"Naymagon","year":"2017","journal-title":"Hemasphere"},{"issue":"25","key":"10.1016\/j.clml.2024.09.001_bib0064","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1182\/blood-2013-02-485888","article-title":"Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis","volume":"122","author":"Cervantes","year":"2013","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2024.09.001_bib0065","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s11899-018-0447-9","article-title":"Management of myelofibrosis-related cytopenias","volume":"13","author":"Bose","year":"2018","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.clml.2024.09.001_bib0066","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2024025802","article-title":"Proposals for Revised International Working Group-European LeukemiaNet Criteria for Anemia Response in Myelofibrosis","author":"Tefferi","year":"2024","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2024.09.001_bib0067","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.3324\/haematol.2013.092155","article-title":"Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I","volume":"98","author":"Verstovsek","year":"2013","journal-title":"Haematol"},{"key":"10.1016\/j.clml.2024.09.001_bib0068","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2147\/OTT.S53348","article-title":"Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes","volume":"7","author":"Verstovsek","year":"2013","journal-title":"Onco Targets Ther"},{"issue":"17","key":"10.1016\/j.clml.2024.09.001_bib0069","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.1182\/bloodadvances.2024012939","article-title":"Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis","volume":"8","author":"Gerds","year":"2024","journal-title":"Blood Adv"},{"issue":"12","key":"10.1016\/j.clml.2024.09.001_bib0070","doi-asserted-by":"crossref","first-page":"E474","DOI":"10.1002\/ajh.26749","article-title":"Limited activity of luspatercept in myelofibrosis and myeloid neoplasms other than myelodysplastic syndromes with ring sideroblasts","volume":"97","author":"Gangat","year":"2022","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.clml.2024.09.001_bib0071","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/ejh.12846","article-title":"Predictive factors for anemia response to erythropoiesis-stimulating agents in myelofibrosis","volume":"98","author":"Hern\u00e1ndez-Boluda","year":"2017","journal-title":"Eur J Haematol"},{"issue":"4","key":"10.1016\/j.clml.2024.09.001_bib0072","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1365-2141.2004.05229.x","article-title":"Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature","volume":"127","author":"Cervantes","year":"2004","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.clml.2024.09.001_bib0073","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1365-2141.2006.06142.x","article-title":"Darbepoetin-alpha for the anaemia of myelofibrosis with myeloid metaplasia","volume":"134","author":"Cervantes","year":"2006","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.clml.2024.09.001_bib0074","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1038\/s41375-022-01637-7","article-title":"Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis","volume":"36","author":"Mesa","year":"2022","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.clml.2024.09.001_bib0075","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1182\/bloodadvances.2021006889","article-title":"A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis","volume":"6","author":"Maffioli","year":"2022","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.clml.2024.09.001_bib0076","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.3324\/haematol.2020.260125","article-title":"The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis","volume":"106","author":"Shoukier","year":"2021","journal-title":"Haematol"},{"issue":"18","key":"10.1016\/j.clml.2024.09.001_bib0077","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1182\/blood-2009-05-224766","article-title":"Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim","volume":"114","author":"Kuter","year":"2009","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2024.09.001_bib0078","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/cncr.32664","article-title":"Life after ruxolitinib: reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis","volume":"126","author":"Palandri","year":"2020","journal-title":"Cancer"},{"issue":"18","key":"10.1016\/j.clml.2024.09.001_bib0079","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.2217\/fon-2021-1358","article-title":"Real-world clinical outcomes of patients with myelofibrosis treated with ruxolitinib: a medical record review","volume":"18","author":"Passamonti","year":"2022","journal-title":"Fut Oncol"},{"issue":"7","key":"10.1016\/j.clml.2024.09.001_bib0080","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1080\/13696998.2020.1741381","article-title":"Patient characteristics and outcomes after ruxolitinib discontinuation in patients with myelofibrosis","volume":"23","author":"Mascarenhas","year":"2020","journal-title":"J Med Econ"},{"issue":"3","key":"10.1016\/j.clml.2024.09.001_bib0081","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00277-017-3194-4","article-title":"Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation","volume":"97","author":"Kuykendall","year":"2018","journal-title":"Ann Hematol"},{"issue":"12","key":"10.1016\/j.clml.2024.09.001_bib0082","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2014.84","article-title":"Definition and management of ruxolitinib treatment failure in myelofibrosis","volume":"4","author":"Pardanani","year":"2014","journal-title":"Blood Cancer Journal"},{"issue":"7","key":"10.1016\/j.clml.2024.09.001_bib0083","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1200\/JOP.19.00506","article-title":"Patterns of ruxolitinib therapy failure and its management in myelofibrosis: perspectives of the canadian myeloproliferative neoplasm group","volume":"16","author":"Gupta","year":"2020","journal-title":"JCO Oncol Pract"},{"issue":"11","key":"10.1016\/j.clml.2024.09.001_bib0084","doi-asserted-by":"crossref","first-page":"763","DOI":"10.2217\/fon-2022-1298","article-title":"Defining ruxolitinib failure and transition to next-line therapy for patients with myelofibrosis: a modified Delphi panel consensus study","volume":"19","author":"Mascarenhas","year":"2023","journal-title":"Fut Oncol"},{"issue":"15","key":"10.1016\/j.clml.2024.09.001_bib0085","doi-asserted-by":"crossref","first-page":"4424","DOI":"10.1182\/bloodadvances.2022008158","article-title":"RR6 prognostic model provides information about survival for myelofibrosis treated with ruxolitinib: validation in a real-life cohort","volume":"6","author":"Scalzulli","year":"2022","journal-title":"Blood Adv"},{"issue":"24","key":"10.1016\/j.clml.2024.09.001_bib0086","doi-asserted-by":"crossref","first-page":"7418","DOI":"10.3390\/jcm11247418","article-title":"Prediction of survival and prognosis migration from gold-standard scores in myelofibrosis patients treated with ruxolitinib applying the RR6 prognostic model in a monocentric real-life setting","volume":"11","author":"Duminuco","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.clml.2024.09.001_bib0087","doi-asserted-by":"crossref","unstructured":"Coltro G, Capecchi G, Maffioli M, et al. Validation and molecular integration of the RR6 model to predict survival after 6 months of therapy with ruxolitinib. Haematol. 2020;109:3398-3403. Published online. doi:10.3324\/haematol.2024.285098.","DOI":"10.3324\/haematol.2024.285098"},{"issue":"9","key":"10.1016\/j.clml.2024.09.001_bib0088","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2013.119","article-title":"Mutations and prognosis in primary myelofibrosis","volume":"27","author":"Vannucchi","year":"2013","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.clml.2024.09.001_bib0089","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1182\/blood-2017-05-783225","article-title":"Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation","volume":"130","author":"Newberry","year":"2017","journal-title":"Blood"},{"issue":"32","key":"10.1016\/j.clml.2024.09.001_bib0090","doi-asserted-by":"crossref","first-page":"4993","DOI":"10.1200\/JCO.22.01972","article-title":"MANIFEST: pelabresib in combination with ruxolitinib for janus kinase inhibitor treatment-na\u00efve myelofibrosis","volume":"41","author":"Mascarenhas","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.clml.2024.09.001_bib0091","doi-asserted-by":"crossref","DOI":"10.1200\/PO.23.00234","article-title":"Discontinuation syndrome with JAK2 selective agents: case presentation and mechanistic insights","author":"Handa","year":"2024","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"10.1016\/j.clml.2024.09.001_bib0092","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41408-020-00392-1","article-title":"Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis","volume":"11","author":"Palandri","year":"2021","journal-title":"Blood Cancer J"},{"issue":"9","key":"10.1016\/j.clml.2024.09.001_bib0093","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1038\/s41409-021-01305-x","article-title":"Trends in allogeneic haematopoietic cell transplantation for myelofibrosis in Europe between 1995 and 2018: a CMWP of EBMT retrospective analysis","volume":"56","author":"McLornan","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"21","key":"10.1016\/j.clml.2024.09.001_bib0094","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1182\/blood-2014-10-608315","article-title":"Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis","volume":"125","author":"Kr\u00f6ger","year":"2015","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2024.09.001_bib0095","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1182\/bloodadvances.2019001084","article-title":"Survival following allogeneic transplant in patients with myelofibrosis","volume":"4","author":"Gowin","year":"2020","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.clml.2024.09.001_bib0096","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/ejh.13294","article-title":"Allogeneic stem cell transplantation for myelofibrosis patients aged \u226565 years","volume":"103","author":"Daghia","year":"2019","journal-title":"Eur J Haematol"},{"issue":"20","key":"10.1016\/j.clml.2024.09.001_bib0097","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1182\/blood-2018-12-890889","article-title":"Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation","volume":"133","author":"Gagelmann","year":"2019","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.clml.2024.09.001_bib0098","doi-asserted-by":"crossref","first-page":"3993","DOI":"10.1182\/bloodadvances.2023009886","article-title":"A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR\/EBMT analysis","volume":"7","author":"Tamari","year":"2023","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.clml.2024.09.001_bib0099","doi-asserted-by":"crossref","first-page":"e204","DOI":"10.1016\/j.bbmt.2019.03.024","article-title":"Comparison of dynamic international prognostic scoring system and myelofibrosis secondary to PV and ET prognostic model for prediction of outcome in polycythemia vera and essential thrombocythemia myelofibrosis after allogeneic stem cell transplantation","volume":"25","author":"Gagelmann","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.clml.2024.09.001_bib0100","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1200\/JCO.2017.76.4886","article-title":"MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis","volume":"36","author":"Guglielmelli","year":"2018","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clml.2024.09.001_bib0101","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/bjh.17469","article-title":"Allogeneic haematopoietic cell transplantation for myelofibrosis: a real-life perspective","volume":"195","author":"Savani","year":"2021","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.clml.2024.09.001_bib0102","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/leu.2015.233","article-title":"Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT\/ELN international working group","volume":"29","author":"Kr\u00f6ger","year":"2015","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.clml.2024.09.001_bib0103","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/ajh.26020","volume":"96","author":"Polverelli","year":"2021","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.clml.2024.09.001_bib0104","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2022.02.004","article-title":"Post-transplantation cyclophosphamide-based graft- versus-host disease prophylaxis with nonmyeloablative conditioning for blood or marrow transplantation for myelofibrosis","volume":"28","author":"Jain","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"10.1016\/j.clml.2024.09.001_bib0105","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/s41375-021-01449-1","article-title":"Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study","volume":"36","author":"Kunte","year":"2022","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.clml.2024.09.001_bib0106","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.bbmt.2015.10.005","article-title":"Outcomes of allogeneic hematopoietic cell transplantation in patients with myelofibrosis with prior exposure to janus kinase 1\/2 inhibitors","volume":"22","author":"Shanavas","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.clml.2024.09.001_bib0107","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1016\/S2352-3026(23)00305-8","article-title":"Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT\/ELN international working group","volume":"11","author":"Kr\u00f6ger","year":"2024","journal-title":"Lancet Haematol"},{"issue":"20","key":"10.1016\/j.clml.2024.09.001_bib0108","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1182\/blood.2023021218","article-title":"How I treat transplant-eligible patients with myelofibrosis","volume":"142","author":"Kr\u00f6ger","year":"2023","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2024.09.001_bib0109","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/leu.2014.86","article-title":"JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET\/PV myelofibrosis","volume":"28","author":"St\u00fcbig","year":"2014","journal-title":"Leukemia"},{"issue":"22","key":"10.1016\/j.clml.2024.09.001_bib0110","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1182\/blood.V128.22.1948.1948","article-title":"Ruxolitinib for myelofibrosis patients relapsing after allogeneic hematopoietic transplantation","volume":"128","author":"Janson","year":"2016","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2024.09.001_bib0111","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1038\/s41375-021-01276-4","article-title":"Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT","volume":"35","author":"Kr\u00f6ger","year":"2021","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.clml.2024.09.001_bib0112","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/s41409-024-02220-7","article-title":"Graft-versus-host disease and impact on relapse in myelofibrosis undergoing hematopoietic stem cell transplantation","volume":"59","author":"Oechsler","year":"2024","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.clml.2024.09.001_bib0113","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/s41409-023-01968-8","article-title":"Spleen volume and length determined by computed tomography impact outcome after allogeneic stem cell transplantation for myelofibrosis","volume":"58","author":"Luther","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"19","key":"10.1016\/j.clml.2024.09.001_bib0114","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa1917635","article-title":"Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease","volume":"382","author":"Zeiser","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.clml.2024.09.001_bib0115","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2033122","article-title":"Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease","volume":"385","author":"Zeiser","year":"2021","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.clml.2024.09.001_bib0116","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1016\/j.bbmt.2018.05.023","article-title":"Peritransplantation ruxolitinib prevents acute graft-versus-host disease in patients with myelofibrosis undergoing allogenic stem cell transplantation","volume":"24","author":"Kr\u00f6ger","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.clml.2024.09.001_bib0117","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1182\/bloodadvances.2021005035","article-title":"Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label study","volume":"6","author":"Ali","year":"2022","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.clml.2024.09.001_bib0118","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/ajh.27274","article-title":"2024 update on allogeneic hematopoietic stem cell transplant for myelofibrosis: a review of current data and applications on risk stratification and management","volume":"99","author":"Ali","year":"2024","journal-title":"Am J Hematol"},{"issue":"9","key":"10.1016\/j.clml.2024.09.001_bib0119","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.jtct.2022.08.005","article-title":"Fine tuning\u201d conditioning protocols for myelofibrosis to reduce graft failure: are we making progress?","volume":"28","author":"McLornan","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.09.001_bib0120","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-178645","article-title":"Updated findings of a phase II study of ruxolitinib pre-, during- and post-hematopoietic stem cell transplantation for patients with primary or secondary myelofibrosis","volume":"142","author":"Hobbs","year":"2023","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2024.09.001_bib0121","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.09.001_bib0122","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1182\/blood-2023-179369","article-title":"Preclinical evaluation of INCB160058 - a novel and potentially disease-modifying therapy for JAK2V617F mutant myeloproliferative neoplasms","volume":"142","author":"Stubbs","year":"2023","journal-title":"Blood"},{"issue":"7414","key":"10.1016\/j.clml.2024.09.001_bib0123","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/nature11303","article-title":"Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy","volume":"489","author":"Koppikar","year":"2012","journal-title":"Nature"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024018044?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024018044?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T06:40:36Z","timestamp":1772606436000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024018044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":123,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S2152265024018044"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.09.001","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions | Choosing and Properly Using a JAK Inhibitor in Myelofibrosis","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}